Interestingly, the findings in TAILORx and RxPONDER trials, which used Oncotype DX 21-gene recurrence score (RS) to stratify patients with ER-positive, HER2-negative, lymph node-negative (TAILORx) or node-positive with 1–3 positive nodes (RxPONDER) breast cancer, suggested that the performance and the used threshold of Oncotype DX depended on the menopausal status. This evidence concerns the gene ESR1 and breast carcinoma.